Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ipatasertib - Genentech

Next Previous
X
Search
Drug Profile

Ipatasertib - Genentech

Alternative Names: GCD 0068; GDC-0068; RG-7440; RO 5532961

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Big Ten Cancer Research Consortium; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; National Cancer Institute (USA); Roche; Roche Farma; SOLTI Breast Cancer Research Group
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Heterocyclic bicyclo compounds; Ketones; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Phase II Gastrointestinal cancer; Haematological malignancies; Ovarian cancer; Solid tumours
  • Phase I/II Endometrial cancer; Prostate cancer
  • Phase I Head and neck cancer
  • No development reported HER2 positive breast cancer

Most Recent Events

  • 01 Jun 2024 Genetech completes a phase-I trial in Prostate cancer (Combination therapy, Hormone refractory) in Ukraine, Moldova, Georgia (PO) (ISRCTN16103425)
  • 31 May 2024 Efficacy and adverse event data from the phase II PATHFINDER trial in Triple negative breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy and adverse event data from the phase II TAPISTRY trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top